New Ferring Head Laments Woeful Neglect Of Women's Health
More Funding Needed To Redress Imbalances
After fighting for years to bridge the gender health gap where many women receive poorer treatment than men from academia and non-profits, Kelle Moley has moved into pharma with Ferring to further her vision.
You may also be interested in...
Cosentyx Becomes First Biologic Approved For HS In Nearly A Decade
The Swiss major should have a considerable first-to-market advantage over other IL-17 biologics from the likes of UCB and Acelyrin that are also targeting the hidradenitis suppurativa space.
Plotting The Path For Pharma To Maintain New-Found Trust
Trustworthiness in the pharmaceutical industry has settled since its peaks during the COVID-19 pandemic but it can move upwards again if companies assume responsibility to inform on wider issues, according to experts at Edelman.
Sanofi Moves Up In MS With Frexalimab Success
Much of the focus on the French major’s MS pipeline has been on the BTK inhibitor tolebrutinib but promising Phase II data on frexalimab have caught the eye.